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Summary Twenty patients with non-Hodgkin's lymphoma were treated with a combination of cyclophosphamide (750 mg m-2, day 1),
epidoxorubicin (60 mg m-2, day 1), vincristine (1.4 mg m-2, day 1) and prednisone (100 mg m-2, days 1-5) every 14 days. Shortening of
intervals was associated with the prophylactic employment of granulocyte colony-stimulating factor (G-CSF; specifically, filgrastim)
administered at a dose of 300 gg subcutaneously from day 6 to day 11. The ratio between actually delivered dose intensity and planned dose
intensity was 1.0 in 18 out the 20 patients. Toxicity was acceptable; response rate and survival are in the expected range. The present study
demonstrated the feasibility of acceleration of chemotherapy cycles to obtain dose intensification in non-Hodgkin's lymphoma.
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Non-Hodgkin's lymphomas represent a large family of neoplastic
diseases with heterogeneous natural history; a series of different
therapeutic approaches should be considered. Chemotherapy is the
mainstay of treatment for many patients, mainly for the inter-
mediate- to high-grade forms.
An association between dose of chemotherapeutic agents and
anti-tumour effect has been established in several experimental
models and suggested in a few clinical reports (Gurney et al,
1993a,b); the availability of haematopoietic growth factors
(G-CSF, granulocyte colony-stimulating factor; and GM-CSF,
granulocyte-macrophage colony-stimulating factor) has rendered
safer the administration ofconventional chemotherapy and feasible
a series ofexperiments on chemotherapy dose intensification.
In the present study we investigated the intensification of
chemotherapy in combination with G-CSF, by shortening intervals
among cycles, in analogy with studies of chemotherapy accelera-
tion carried out in breast (Ardizzoni et al, 1994), ovarian (Pronzato
et al, 1996), bladder (Pronzato et al, 1997) and small-cell lung
cancer (Ardizzon et al, 1993).
PATIENTS AND METHODS
Patients
To enter this study patients were required to fulfil the following
criteria: histological diagnosis of non-Hodgkin's lymphoma;
histological features of intermediate- or high-grade lymphoma
according to the Working Formulation (excluding lymphoblastic
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lymphoma) groups D, E, F, G, H and J; absence of cardiovascular
diseases on the basis of clinical examination and electrocardio-
gram (ECG); adequate marrow reserve (pretreatment values,
Hb > 10 g dl-'; WBC > 3.5 x 109 1-1; platelets > 150 x 109 1-1); a
serum creatinine level of < 1.0 mg dl-'; a serum bilirubin level of
< 1.2 mg/dl; no concomitant acquired immunodeficiency syn-
drome; no concomitant neoplastic diseases. The patients had to be
previously untreated by chemotherapy. The nature and the purpose
of the study were discussed fully with all patients and informed
consent was obtained from all those enrolled.
Treatment
Patients were treated with the following regimen (accelerated
CEOP): cyclophosphamide 750 mg m-2 i.v. day 1; epidoxorubicin
60 mg m-2 i.v. day 1: vincristine 1.4 mg m-2 i.v. day 1; prednisone
100 mg/M-2 orally day 1-5; G-CSF (filgrastim) 300 ,ug subcuta-
neously days 6-11. All the patients received an antiemetic
premedication by ondansetron. Cycles were repeated every
14 days provided that bone marrow recovery had occurred on the
day ofrecycle (WBC > 3.0 x 1091-1 and platelets > 100 x 1091-').
In the case of incomplete marrow recovery, delays were planned
for all the drugs until the above-mentioned values were reached.
Response and toxicity were evaluated by the WHO criteria
(Miller et al, 1981).
Study design
We planned this study to evaluate the feasibility of dose intensifi-
cation by acceleration, considering a therapeutic success (in terms
of dose intensity) the achievement of at least 80% of the planned
dose intensity (actually received-planned dose intensity ratio) in
six cycles, on the basis ofour previous experience in breast cancer
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Table 1 Characteristics of patients
Age (range)
Sex: male/female
Median WHO performance status (range)
B symptoms
Present
Absent
Stage
Local (stage I-Il)
Advanced (stage III-IV)
Mass size
<10cm
>10cm
Number of sites involved
1
2
>2
Extranodal disease
Present
Absent
Bone marrow involvement
Yes
No
Serum LDH
Normal
Elevated
66 years (40-70 years)
13/7
1 (1-2)
8
12
10
10
12
8
2
8
10
6
14
5
15
14
6
Serum albumin
<3.5 g dl-'
>3.5 g dl-1
Classification by International Index prognostic categories
Low risk (0-1)
Low-intermediate risk (2)
High-intermediate risk (3)
High risk (4)
2
18
5
12
2
1
(Pronzato, 1989). The dose intensity, expressed in milligrams per
square metre of body surface area per week, was calculated for
each drug by dividing the total amount of drug (planned or
received) by the duration of chemotherapy (Hryniuk, 1984). The
ratio between the actually received dose intensity and the planned
dose intensity was the same for each drug, as no differential reduc-
tions in dose or delays in time of administration were foreseen or
applied. To determine the sample size minimizing the number of
patients receiving a 'not feasible treatment', we applied the
Simon's two-stage minimax design for phase II clinical trials
(Simon, 1989). The primary objective of the trial was to explore
the possibility of administering accelerated chemotherapy and we
identified our success rate as 90% of patients able to receive 80%
or more of the planned dose and the schedule of accelerated
chemotherapy without delays or unexpected toxicity. We were not
interested in a success rate less than 70%, as we considered that an
increase in dose intensity is only likely to produce benefit if it is
applied to the large majority of patients. With these premises, for
alpha and beta error equal to 10%, we planned to accrue 16
patients in the first stage and to move further on the second stage
of nine more patients if more than 11 successes were observed in
the first 16 patients. Finally, we planned to accept the new regimen
for further clinical trials if more than 20 successes (80% or more
of the planned dose intensity in six cycles) were observed out of
25 patients.
RESULTS
Twenty patients entered the trial. The main characteristics of the
patients are shown in Table 1. All the patients had intermediate- to
high-grade non-Hodgkin's lymphoma requiring chemotherapy. The
Working Formulation Group was D in two patients, E in five
patients, F in three patients, G in eight patients and H in two
patients. Nine patients with limited disease were treated with radio-
therapy of the involved fields only after the last cycle of
chemotherapy was administered. Two patients with disseminated
disease experiencing a complete response were treated with consol-
idation chemotherapy. However, the present study regards only the
analysis ofthe first six consecutive cycles ofaccelerated CEOP.
At the end of the first stage of accrual we noted that 14 out of
the 16 patients entered had completed the programme with a ratio
of actually received-planned dose intensity of 1.0. Early accep-
tance of the treatment is not permitted at the end of the first stage,
and a further four patients were entered, again achieving adequate
dose intensity. Overall, 18 patients received six cycles without
delay or dose reduction and two patients had a delay of 1 and 2
weeks. In Table 2 the drug dose intensities of different regimens
are shown. As can be seen the dose intensity (planned and actually
received) for cyclophosphamide and anthracycline was higher in
the present trial than in classical regimens.
Maintenance ofthe planned dose intensity (100% ofthe dose at
due times), low toxicity, good acceptance of the acceleration by
the patients and our previous experience with accelerated
chemotherapy prompted us to stop the trial even though the second
stage of the accrual was not completed. We observed 15 objective
responses (eight complete and seven partial). Median survival was
24 months (range 6-36+). Median survival of responders was
32 months (12+-36+)
Toxicity was moderate in this study; the main side-effects of
chemotherapy and filgrastim are shown in Table 3. Notably, all the
treatment was administered in an outpatient setting and no patient
needed to be admitted because of treatment toxicity. A mild
decline in haemoglobin and platelets was observed during the
treatment (Table 4); red cell transfusion was needed in three cases.
DISCUSSION
After classical combination chemotherapy - the so-called first-
generation regimens - showed the ability to cure a fraction of
patients with intermediate- to high-grade lymphoma, improvements
were thought to be achieved by means ofchemotherapy intensifica-
tion dose (Fisher et al, 1983; Longo et al, 1991; Klimo and Connors,
1995). Although preliminary studies invariably showed very high
response rates for the so-called second- and third-generation
regimens, a definitive demonstration of superiority over the first-
generation combinations, in particular the CHOP regimen
(cyclophosphamide, doxorubicin, vincristine and prednisone), has
not been reached (Fisher et al, 1993; Cooper et al, 1994).
One of the theoretical reasons in favour of second- to third-
generation regimens is the dose intensification of chemotherapy;
on the other hand, dose intensity of the two main drugs, i.e.
cyclophosphamide and doxorubicin, decreased because of the
concomitant use ofother drugs (Fisher et al, 1993). Dose intensity
is defined as the amount of drug administered per unit of time
(usually expressed as mg m-2 week-'); it was extensively studied in
the 1980s by Hryniuk and his group (Hryniuk, 1984). A retrospec-
tive analysis on the association between projected dose intensity of
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Table 2 Drug dose intensity in different studies (mg m-2 week-1)
CPA ADM EPI VCR
Present study (planned) 375 - 30 0.7
Present study (actually received) 365 - 29 0.68
CHOP (planned) 250 18 - 0.46
MACOP-B (planned) 125 25 - 0.70
ProMACE-CytaBOM (planned) 217 8.3 - 0.46
ProMACE-CytaBOM (actually received) 175.12 6.7 - 0.40
*CPA, cyclophosphamide; ADM, doxorubicin; EPI, epidoxorubicin; VCR, vincristine. aSee reference Longo et al (1991).
Table 3 Side-effects (no. of patients) according to the WHO scale
Grade 0 1 2 3-4
Nausea and vomiting 7 10 3 -
Anaemia 5 7 5 3
Leucopenia 5 13 2 -
Neutropenia 4 14 2
Thrombocytopenia 19 1 -
Neuropathy 12 6 2 -
Hair loss - - 4 16
Pain 12 2 5 1
Fever 13 3 4 -
Diarrhoea 18 2 - -
22 different studies and their response rate showed that dose inten-
sity may improve the remission rate in advanced-stage interme-
diate-grade lymphoma (Meyer et al, 1993). A retrospective
analysis showed a better survival for patients having received a
relative dose intensity >70% of cyclophosphamide and doxoru-
bicin (Lepage et al, 1993). Also, a group at Stanford University
(Kwak et al, 1990) found that actually received dose intensity is
correlated with survival improvement: the received dose intensity
ofdoxorubicin was the single most important predictor ofsurvival.
In the LNH-84 protocol the induction chemotherapy was a high
dose intensity sort of CHOP and the favourable results may be
determined by the increased dose intensity of doxorubicin and
cyclophosphamide (Coiffier, 1995). Although these studies are
retrospective in nature, they serve as a basis to the design of
prospective trials specifically aimed at exploring the issue of dose
intensity.
The dose intensity ofdrugs included in cyclic combinations may
be increased in two ways: increasing the doses of each cycle or
shortening the intervals between cycles. Haematopoietic growth
factors permit the shortening of intervals between cycles of
chemotherapy, and G-CSF/GM-CSF have been demonstrated to
be able to protect from consequences of leucopenia in the cases of
conventional but aggressive regimens. Pettengell et al (1992)
demonstrated that the protection from myelosuppression induced
by VAPEC-B with the prophylactic use offilgrastim determined a
more rapid recovery of neutrophils, resulting in a significantly
lower incidence ofdose reductions or cycle delays. Chemotherapy
dose could be increased in two studies by means of G-CSF or
GM-CSF (Shipp et al, 1995; Gordon et al, 1996).
In a randomized study carried out in breast cancer patients the
intervals between cycles of cyclophosphamide, epidoxorubicin and
fluorouracil were reduced and the dose intensity increased by
employment of GM-CSF (Ardizzoni et al, 1994). In another study,
in breast cancer, dose escalation and interval reduction were
randomly compared, resulting in a higher dose intensity with the
Table 4 White blood cell (WBCs), neutrophil (N), platelet (PLT) count and
haemoglobin (Hb) before first and sixth cycle: median value (range)
Before first cycle Before sixth cycle
WBC (x 1091-) 6.1 (4.8-16.4) 6.5 (4.4-51.7)
N (x 109 I-') 4.4 (3.3-11.9) 4.9 (3.9-43.9)
PLT (1091-1) 221 (186-302) 183 (140-243)
Hb (g dl-1) 13.4 (10.4-16.8) 10.9 (10.6-14.1)
interval reduction (Lalisang et al, 1997). In other pilot trials the
acceleration was studied in ovarian (Kehoe et al, 1994; Pronzato
et al, 1996), bladder (Pronzato et al, 1997) and small-cell lung
cancer (Ardizzoni et al, 1993). In analogy with these trials of
chemotherapy acceleration, we studied the shortenings of intervals
between cycles of a combination of cyclophosphamide, epidoxo-
rubicin, vincristine and prednisone. In this schedule we adopted
epidoxorubicin instead ofthe parentcompounddoxorubicin, consid-
ering its more favourable toxic profile and assuming an anti-tumour
equivalence of 1.2:1.0, based on the fact that to achieve equimyelo-
toxicity epidoxorubicin shouldbe administered at adose 20% higher
than that of doxorubicin (Mouridsen et al, 1990). Therefore, our
dose of epidoxorubicin may be considered analogous to that of
doxorubicin in the classical CHOP, whereas the other two drugs
were at the same dose as in the conventional CHOP.
In this study, we obtained interesting results in terms ofresponse
rate and survival. Our scheme proved feasible and devoid ofexces-
sive toxicity, including use in older patients, who represent more
than half of our series. Notably, all the treatments were carried out
in an outpatient setting and admission was not needed in any case.
Acceleration may be an important way to achieve safe dose inten-
sification. In advanced ovarian cancer the dose increase of each
cycle with unchanged intervals did translate to an increase in side-
effects and limitation of dose intensification (Conte et al, 1996).
However, acceleration of the same drugs has been shown to be
feasible (Pronzato et al, 1996). In breast cancer, chemotherapy
acceleration resulted in a more pronounced dose intensification with
respect to increase in dosage per cycle (Lalisang et al, 1997).
Haematopoietic growth factors permitted safe acceleration of
chemotherapy and, on the basis ofthe results obtained in the present
and in other studies (Shipp et al, 1995; Gordon et al, 1996), further
dose intensifications may be achieved. Nevertheless, recent observa-
tions on the leucemogenic potential ofalkylators/anthracycline dose
intensification and growth factors should be taken into consideration
(Brodsky et al, 1997; De Cillis et al, 1997).
In conclusion, our scheme was feasible and active and, if one
looks at dose intensification as a major issue, our accelerated
regimen warrants further consideration in phase II-III trials.
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